Relmada Therapeutics Inc (OTCMKTS:RLMD) shares saw unusually-high trading volume on Wednesday . Approximately 73,537 shares traded hands during mid-day trading, an increase of 90% from the previous session’s volume of 38,618 shares.The stock last traded at $34.46 and had previously closed at $33.22.

The company has a 50 day moving average of $27.35 and a 200 day moving average of $9.33.

In other Relmada Therapeutics news, Director Paul Edward Kelly purchased 5,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were purchased at an average cost of $30.00 per share, with a total value of $150,000.00. Company insiders own 5.20% of the company’s stock.

About Relmada Therapeutics (OTCMKTS:RLMD)

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.

Featured Article: How do taxes affect a CDs total return?

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with's FREE daily email newsletter.